Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Non-targeted therapy in Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC) and Thymic Epithelial Tumors (TET).

IF 2 4区医学 Q3 ONCOLOGY

Oncology Research and Treatment Pub Date : 2025-04-01 DOI:10.1159/000545493

Marie-Elisabeth Leßmann, Christine Sibbert, Lea Reitnauer, Sophie Heinzen, Maximilian Webendörfer, Tobias Raphael Overbeck, Frank Griesinger, Annalen Bleckmann, Marcel Wiesweg, Amanda Tufman, Michael Thomas, Cornelia Kropf-Sanchen

{"title":"Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Non-targeted therapy in Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC) and Thymic Epithelial Tumors (TET).","authors":"Marie-Elisabeth Leßmann, Christine Sibbert, Lea Reitnauer, Sophie Heinzen, Maximilian Webendörfer, Tobias Raphael Overbeck, Frank Griesinger, Annalen Bleckmann, Marcel Wiesweg, Amanda Tufman, Michael Thomas, Cornelia Kropf-Sanchen","doi":"10.1159/000545493","DOIUrl":null,"url":null,"abstract":"<p><p>The European Society for Medical Oncology (ESMO) Congress 2024 presented pivotal new data across various trials that continue to explore the nuances of immunotherapy (ICI) in non-small-cell lung cancer (NSCLC) and small cell lung cancer (SCLC). In early-stage lung cancer, additional data was presented for immune-checkpoint-inhibitor therapy in the perioperative setting, aiming to deepen the knowledge of potential predictive markers. An update from the ADRIATIC study on limited-stage SCLC provided new insights into various subgroups, including the impact of different aspects of radiation therapy and the choice of platinum doublet chemotherapy. In the context of palliative treatment of NSCLC several studies focused on optimizing first-line therapy, e.g. by incorporating anti-TIGIT or LAG-3 antibodies. Additionally, the issue of targeting resistance pathways in patients with advanced NSCLC was addressed. Deescalation of therapy was the aim of low-dose versus standard-dose Pembrolizumab in advanced NSCLC. Preliminary data in thymic epithelial tumors (TET) and immune-checkpoint-inhibitor (ICI) therapy in combination with Lenvatinib were presented in the PECATI trial.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"1-9"},"PeriodicalIF":2.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545493","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The European Society for Medical Oncology (ESMO) Congress 2024 presented pivotal new data across various trials that continue to explore the nuances of immunotherapy (ICI) in non-small-cell lung cancer (NSCLC) and small cell lung cancer (SCLC). In early-stage lung cancer, additional data was presented for immune-checkpoint-inhibitor therapy in the perioperative setting, aiming to deepen the knowledge of potential predictive markers. An update from the ADRIATIC study on limited-stage SCLC provided new insights into various subgroups, including the impact of different aspects of radiation therapy and the choice of platinum doublet chemotherapy. In the context of palliative treatment of NSCLC several studies focused on optimizing first-line therapy, e.g. by incorporating anti-TIGIT or LAG-3 antibodies. Additionally, the issue of targeting resistance pathways in patients with advanced NSCLC was addressed. Deescalation of therapy was the aim of low-dose versus standard-dose Pembrolizumab in advanced NSCLC. Preliminary data in thymic epithelial tumors (TET) and immune-checkpoint-inhibitor (ICI) therapy in combination with Lenvatinib were presented in the PECATI trial.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology Research and Treatment ONCOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.